In the JUPITER trial [4], involving apparently healthy men aged 50 years or more and women aged 60 years or more without hyperlipidaemia but with elevated high-sensitivity C-reactive protein (CRP) levels, rosuvastatin significantly reduced all-cause mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.67–0.97), and the most recently published meta-analysis unequivocally supports statin-based primary prevention [5], with an odds ratio (OR) of 0.86 (95%CI 0.79–0.94) [5]. The gene discussed is CRP; the disease is hyperlipidemia.